Bio-Rad Laboratories maintains substantial international operations, accounting for approximately 60% of net sales, which underpin its global reach but also introduce significant compliance and operational complexities. The company posted solid overall profits in 2025, despite a Q4 earnings miss that tempered market enthusiasm. Intense competition from larger industry players constrains pricing flexibility, while regulatory and geopolitical risks loom large due to Bio-Rad’s dispersed sales network. Nevertheless, the firm’s strong liquidity and innovation capabilities support its strategic positioning amid persistent uncertainties.